HSBC has reiterated its ‘Buy’ rating on Sun Pharma, setting a target price of ₹2,000, indicating a 21% upside from the current market price of ₹1,657 (as of March 11). The brokerage remains optimistic about Sun Pharma’s long-term growth, particularly following its acquisition of Checkpoint Therapeutics.
The deal adds Unloxcyt, an FDA-approved oncology treatment, to Sun Pharma’s portfolio, strengthening its specialty drug segment. HSBC sees this acquisition as crucial for sustaining long-term growth, reinforcing Sun Pharma’s expansion in the high-margin specialty drug business.
With a strong pipeline of specialty drugs and increasing focus on innovative treatments, HSBC believes Sun Pharma is well-positioned for future growth. Investors will be closely watching the impact of Unloxcyt’s commercialization on the company’s earnings in the coming quarters.
Disclaimer: The above stock recommendations are based on brokerage reports and do not constitute financial advice. Investors are advised to conduct their own research before making investment decisions.
